Literature DB >> 19351633

Plasma apelin concentration is depressed following acute myocardial infarction in man.

Robin A P Weir1, Kwok Shiong Chong, Jonathan R Dalzell, Colin J Petrie, Charles A Murphy, Tracey Steedman, Patrick B Mark, Theresa A McDonagh, Henry J Dargie, John J V McMurray.   

Abstract

AIMS: Apelin, a novel peptide with a putative role in cardiovascular homeostasis, has gained interest as an endogenous inotrope, but has yet to be described following acute myocardial infarction (AMI) in man. We aimed to characterize plasma apelin concentrations following AMI and to examine its relationship with clinical and prognostic biomarkers. METHODS AND
RESULTS: Plasma concentrations of apelin, N-terminal probrain natriuretic peptide (NT-proBNP), norepinephrine, and arginine vasopressin were measured in 100 patients [mean age 58.9 +/- 12 (SD) years, 77% male] admitted with AMI, with echocardiographic left ventricular (LV) ejection fraction <40%, at mean 46 h after admission and at 24 weeks. Cardiac magnetic resonance imaging was performed pre-discharge and at 24 weeks. Thirty-eight subjects with no cardiac history acted as controls. Apelin concentration was reduced early after AMI (0.54 +/- 0.25 vs. 3.22 +/- 3.01 ng/mL, P <0.001) and remained low at 24 weeks, although it did increase significantly from baseline to 0.62 +/- 0.36 ng/mL, P = 0.030. Apelin had no relationship with any parameter of LV function over time. A relationship was found between baseline apelin and norepinephrine (r = 0.26, P = 0.008). Both NT-proBNP and norepinephrine correlated with adverse ventricular function after AMI.
CONCLUSION: Plasma apelin concentration is reduced early after AMI, increases significantly over time, but remains depressed at 24 weeks.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351633     DOI: 10.1093/eurjhf/hfp043

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  21 in total

Review 1.  Adipose tissue and vascular inflammation in coronary artery disease.

Authors:  Enrica Golia; Giuseppe Limongelli; Francesco Natale; Fabio Fimiani; Valeria Maddaloni; Pina Elvira Russo; Lucia Riegler; Renatomaria Bianchi; Mario Crisci; Gaetano Di Palma; Paolo Golino; Maria Giovanna Russo; Raffaele Calabrò; Paolo Calabrò
Journal:  World J Cardiol       Date:  2014-07-26

2.  Apelin: a novel marker for the patients with first ST-elevation myocardial infarction.

Authors:  Agnieszka M Kuklinska; Bozena Sobkowicz; Robert Sawicki; Wlodzimierz J Musial; Ewa Waszkiewicz; Swietlana Bolinska; Jolanta Małyszko
Journal:  Heart Vessels       Date:  2010-07-31       Impact factor: 2.037

Review 3.  The Role of Adipocytokines in Coronary Atherosclerosis.

Authors:  Luca Liberale; Aldo Bonaventura; Alessandra Vecchiè; Matteo Casula; Franco Dallegri; Fabrizio Montecucco; Federico Carbone
Journal:  Curr Atheroscler Rep       Date:  2017-02       Impact factor: 5.113

4.  Effects of acute intravenous infusion of apelin on left ventricular function in dogs with advanced heart failure.

Authors:  Mengjun Wang; Ramesh C Gupta; Sharad Rastogi; Smita Kohli; Michael S Sabbah; Kefei Zhang; Paula Mohyi; Manuela Hogie; Yvan Fischer; Hani N Sabbah
Journal:  J Card Fail       Date:  2013-07       Impact factor: 5.712

5.  Prognostic Value of Combining Apelin-12 and Estimated Glomerular Filtration Rate in Patients with ST-Segment Elevation Myocardial Infarction.

Authors:  Yue Liu; Huasong Xia; Meng Li; Yi Chen; Yanqing Wu
Journal:  J Interv Cardiol       Date:  2022-06-24       Impact factor: 1.776

6.  Apelin-13 administration protects against ischaemia/reperfusion-mediated apoptosis through the FoxO1 pathway in high-fat diet-induced obesity.

Authors:  Frederic Boal; Andrei Timotin; Jessica Roumegoux; Chiara Alfarano; Denis Calise; Rodica Anesia; Angelo Parini; Philippe Valet; Helene Tronchere; Oksana Kunduzova
Journal:  Br J Pharmacol       Date:  2016-04-20       Impact factor: 8.739

7.  Apelin and pulmonary hypertension.

Authors:  Charlotte U Andersen; Ole Hilberg; Søren Mellemkjær; Jens E Nielsen-Kudsk; U Simonsen
Journal:  Pulm Circ       Date:  2011 Jul-Sep       Impact factor: 3.017

8.  Targeting the ACE2 and Apelin Pathways Are Novel Therapies for Heart Failure: Opportunities and Challenges.

Authors:  Seyyed M R Kazemi-Bajestani; Vaibhav B Patel; Wang Wang; Gavin Y Oudit
Journal:  Cardiol Res Pract       Date:  2012-05-13       Impact factor: 1.866

9.  Structural apelin analogues: mitochondrial ROS inhibition and cardiometabolic protection in myocardial ischaemia reperfusion injury.

Authors:  Oleg Pisarenko; Valentin Shulzhenko; Irina Studneva; Yulia Pelogeykina; Alexander Timoshin; Rodica Anesia; Philippe Valet; Angelo Parini; Oksana Kunduzova
Journal:  Br J Pharmacol       Date:  2015-04-23       Impact factor: 8.739

Review 10.  Browning of White Adipose Tissue as a Therapeutic Tool in the Fight against Atherosclerosis.

Authors:  Christel L Roth; Filippo Molica; Brenda R Kwak
Journal:  Metabolites       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.